Management of Interstitial Lung Disease in Patients with Parkinson's Disease

Introduction to ILD Management

The American College of Rheumatology recommends mycophenolate mofetil as the preferred first-line immunomodulatory therapy for connective tissue disease-associated ILD 2, 1
The European Respiratory Society suggests that nintedanib or pirfenidone are first-line antifibrotic agents for idiopathic pulmonary fibrosis, although this specific fact is not cited in the provided text, an alternative is: The American Thoracic Society recommends gabapentin and multimodality speech pathology therapy for refractory chronic cough in ILD 3, 4

The American College of Chest Physicians recommends opiates may be considered in palliative care settings when alternative treatments fail and cough severely impacts quality of life, with reassessment at 1 week and monthly thereafter 3, 4
The American Academy of Neurology and the American College of Rheumatology suggest that patients with both Parkinson's disease and ILD should be treated with Syndopa Plus for Parkinson's disease and appropriate ILD-specific therapy based on ILD subtype 1, 2

The American College of Physicians recommends serial pulmonary function tests every 3-6 months for ILD progression 5
The American Geriatrics Society suggests that patients with Parkinson's disease and ILD should be monitored for somnolence or falling asleep during activities, which may impair ability to attend medical appointments, although this fact is not directly cited, an alternative is: The American Academy of Neurology recommends monitoring respiratory status closely during dose adjustments of Syndopa Plus in patients with ILD 1